Nov 06, 2013, 09.32 PM IST
The company, however, said Medicine and Healthcare Products Regulatory Agency, UK, (UKMHRA) has eased the restrictions to an extent allowing it to supply most of the products manufactured at the said facility to the UK.
Like this story, share it with millions of investors on M3
Wockhardt may face £1 mn hit due to Kadaiya unit lapses
The company, however, said Medicine and Healthcare Products Regulatory Agency, UK, (UKMHRA) has eased the restrictions to an extent allowing it to supply most of the products manufactured at the said facility to the UK.
Like this story, share it with millions of investors on M3
Wockhardt may face £1 mn hit due to Kadaiya unit lapses
The company, however, said Medicine and Healthcare Products Regulatory Agency, UK, (UKMHRA) has eased the restrictions to an extent allowing it to supply most of the products manufactured at the said facility to the UK.
Also read: Taking corrrective measures on regulatory issues: Wockhardt
The company, however, said Medicine and Healthcare Products Regulatory Agency, UK, (UKMHRA) has eased the restrictions to an extent allowing it to supply most of the products manufactured at the said facility to the UK.
Wockhardt has received a communication from UKMHRA whereby they have allowed manufacturing and supply most of the products manufactured at the said facility and assessed to be critical to public health, the company said in a filing to the BSE.
"As a result the net impact on the annualized consolidated revenue is expected to be less than £1 million, out of the total annual consolidated revenue of approximately £18 million, from the said facility," the company said.
Last month, UKMHRA had imposed restrictions on import of medicines made at the Mumbai-based firm's unit at Kadaiya for violation of norms, the second Wockhardt plant to face such action in as many weeks.
Earlier, the UK health regulator had taken action against the company's Chikalthana facility in Maharashtra, from where good manufacturing certification was withdrawn last month, and the export-oriented plant at Waluj which came under an import alert in July this year.
Shares of Wockhardt today closed at Rs 470.45 on the BSE, up 5 percent from their previous close.
Wockhardt stock price
On November 06, 2013, Wockhardt closed at Rs 470.45, up Rs 22.40, or 5.00 percent. The 52-week high of the share was Rs 2166.05 and the 52-week low was Rs 344.15.
The company's trailing 12-month (TTM) EPS was at Rs 32.23 per share as per the quarter ended September 2013. The stock's price-to-earnings (P/E) ratio was 14.6. The latest book value of the company is Rs 74.56 per share. At current value, the price-to-book value of the company is 6.31.
Anda sedang membaca artikel tentang
Wockhardt may face £1 mn hit due to Kadaiya unit lapses
Dengan url
https://citraasa.blogspot.com/2013/11/wockhardt-may-face-aa1-mn-hit-due-to.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Wockhardt may face £1 mn hit due to Kadaiya unit lapses
namun jangan lupa untuk meletakkan link
Wockhardt may face £1 mn hit due to Kadaiya unit lapses
sebagai sumbernya
0 komentar:
Posting Komentar